 OncLive | Updated BOLERO-2 Data Support Efficacy of Everolimus in Breast Cancer OncLive Updated results from the BOLERO-2 trial support the study's earlier findings that mTOR kinase inhibitor everolimus improves survival for postmenopausal patients with breast cancer, according to 18-month follow-up data presented at the American Society ... Novartis launches breast cancer drug Afinitor in UK Afinitor's new UK indication launched 20/20 GeneSystems Developing mTOR Pathway Test to Predict Herceptin ... |
